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Abstract: Three new physalin steroids, physalin III (1), physalin IV (2), 3-O-methylphysalin X (3), together with five known  
physalins (4–8) were isolated from the 80% EtOH extract of calyces of Physalis alkekengi var. franchetii. The structures of the new 
compounds were revealed through 1D and 2D NMR and mass spectroscopic studies. 
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Introduction 
The genus of Physalis (Solanaceae), including about 120 
species, is widely distributed throughout South and North 
America, which also includes five species, and two variations 
which also can be found in China1. The plant Physalis 
alkekengi var. franchetii, is used in traditional Chinese  
medicine2, and is chiefly used for the treatment and prevention 
of tumors, leishmaniasis, sore throat, cough, eczema, hepatitis 
and urinary problems3. The chemical constituents of P. 
alkekengi var. franchetii are mainly composed of alkaloids, 
flavonoids, sterols, fatty acids, amino acids, and steroids4. 
Physalins, as one of the characteristic constituents from P. 
alkekengi var. franchetii, is a type of steroids with 16,24-
cyclo-13,14-seco-ergostane skeleton which has been  
established by X-ray crystallographic analysis5–7.  
Neophysalins, are another characteristic structure, and are  
transformed from physalins through an acid-induced benzilic 
acid-type rearrangement reaction8. Until recently, more than 
50 physalins and neophysalins have been identified from P. 
alkekegi var. franchetii, P. agulata, P. lancifolia and P.  
minima. Physalins and neophysalins have tremendous  
biological activities, including anti-tumor9, anti-microbial10, 
anti-malarial11, immunosuppressive12, anti-inflammatory13,14, 
immunomodulatory15, cytotoxic16, and trypanocidal17,18 effects. 
In this study, five physalins (1, 2, 4–6) and three  
neophysalins (3, 7, 8) were isolated from P. alkekengi var. 
franchetii, three of which (1–3) were new. Their chemical 
structures and their elucidation are described herein. 
 
Results and Discussion 
Compound 1 was obtained as a white powder. The molecular
formula of 1 was determined to be C28H32O12 by HREIMS 
(m/z 560.1885, [M]+; calcd 560.1894) and NMR data (Table 1). 
The 1H NMR spectrum of 1 (in pyridine-d5) showed four  
methyl signals at δH 1.29, 1.47, 1.65, and 2.02, four oxygenated
signals at δH 4.01 (H-4), 3.54 (H-6), 5.70 (H-7) and 4.73  
(H-22), and two olefinic proton signals at δH 6.24 (H-2) and 
7.19 (H-3). The 13C DEPT spectrum of 1 (in pyridine-d5)  
displayed the presence of twenty-eight carbons, including four 
methyls, three methylenes, ten methines (two olefinic carbons 
and four oxymethanes), eleven quaternary carbons (two ketone 
groups, two lactone groups, four oxygenated carbons, and one 
ketal carbon). These signals indicated the structural similarity 
of 1 and physalin J19. The chemical shift of the ketal carbon at 
C-14 (δC 103.4) of 1 differently from that (δC 107.8) of  
physalin J, together with one more methyl signal and less an 
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bridge was ruptured. This was further determined by the 
HMBC correlations (Figure 1) from Me-27 (δH 1.29) to C-25 
(δC 42.4) and C-26 (δC 173.0). Moreover, the HMBC  
correlations from δH 1.65 (H-19), 6.24 (H-2), and 7.19 (H-3) to δC 202.9 (C-1) demonstrated the presence of an conjugated  
2-en-1-one group, and the 1H-1H COSY correlations of δH 7.19 
(H-3)/δH 4.01 (H-4) revealed that there existed an hydroxyl 
group at C-4. An oxymethine in 1 instead of a methene in  
physalin J suggests that one hydroxyl group could be located 
at C-7, which was confirmed by the 1H-1H COSY correlations 
of δH 3.54 (H-6)/δH 5.70 (H-7) and δH 5.70 (H-7)/δH 2.93 (H-8). 
The relative configurations of H-8 and Me-28 in the physalin 
skeleton were established to be β-oriented by X-ray.20,21 Thus, 
the NOE correlations (Figure 1) of H-4/H-6, H-6/H-7, H-7/H-
8β, and H-27/Me-28 established the relative configuration of 
OH-4 and OH-7 to be α-oriented and Me-27 to be β-oriented. 
Hence, the structure of compound 1 was identified to be  
physalin III (1). 
Compound 2 was obtained as a colorless needle crystal. The 
molecular formula of 2 was determined to be C28H32O12 on the 
basis of HREIMS (m/z 560.1854, [M]+; calcd 560.1894) and 
NMR data (Table 1). The NMR data of 2 were similar to those 
of physalin Z22, and the differences between them were two of 
the double-bond carbon signals in physalin Z were replaced by 
two oxygenated methine signals in 2 located at C-6 and C-7, 
which were deduced by 1H-1H COSY correlations of H-8 (δH 
3.39)/H-7 (δH 5.23) and H-7 (δH 5.23)/H-6 (δH 4.79) and by 
HMBC correlations from H-6 to C-10, C-4, C-8, C-7, and C-5, 
from H-7 to C-6, C-5, C-8, and C-14. The ROESY  
correlations (Figure 2) of H-6/H-7 and H-7/H-8β revealed that 
OH-C(6) and OH-C(7) were α-oriented. So the structure of 
compound 2 was deduced and named as physalin IV (2). 
Compound 3 was obtained as an amorphous yellow powder. 
The molecular formula of 3 was determined as C29H32O10  
using HREIMS and NMR data (Table 1). These NMR data of 
3 were similar to those of physalin X23, except the presence of 
an additional methoxyl group. Comparing with physalin X, the 
chemical shift of C-3 (δC 76.7) at down field and the HMBC 
correlation (Figure 3) of OMe (δH 3.27) with C-3 in 3 indicated
a methoxyl group at C-3. The relative configuration of Me-19 
and H-16 in physalin skeleton were established to be β-
oriented by X-ray.20,21 So the relative configuration of 3-OMe 
could be determined as α-oriented by the NOE correlations of 
Me-19/H-3 and H-16/H-3. Hence, the structure of compound 3 
was identified to be 3-O-methylphysalin X (3). 
Table 1. 1H NMR (600 MHz) and 13C DEPT (150 MHz) data of compounds 1–3 
 
No. 
physalin III (1)a  
 
physalin IV (2)a  
 
3-O-methylphysalin X (3)b 
δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type
1  202.9, C    212.3, C   213.8, C 
2 6.24, d (9.8) 132.8, CH  3.12, dd (11.7, 5.4); 2.85, dd (11.7, 5.7) 47.1, CH2  3.13, dd (13.4, 6.5); 2.62, m 41.2, CH2 
3 7.19, dd (9.8, 6.5) 145.6, CH  4.67, dd (5.7, 5.4) 67.7, CH  4.42–4.38, m 76.7, CH 
4 4.01, d (6.3) 70.3, CH  6.32, d (4.4) 130.5, CH  5.70, d (4.1) 122.4, CH 
5  66.2, C   145.8, C   142. 8, C 
6 3.54, br. s 62.9, CH  4.79, d (3.8) 77.4, CH  6.28, dd (10.4, 1.5) 127.5, CH 
7 5.70, br. s 65.4, CH  5.23, dd (3.5, 1.6) 70.6, CH  6.17, dd (10.4, 3.4) 127.9, CH 
8 2.93, m 44.1, CH  3.39, dd (11.7, 1.6) 43.8, CH  2.81, m 47.7, CH 
9 3.45, m 32.2, CH  2.11, dd (11.7, 2.7) 32.2, CH  2.71–2.74, m 32.8, CH 
10  49.8, C   53.3, C   51.0, C 
11 2.89, m 20.4, CH2  1.63–1.54, m; 2.34, m 23.9, CH2  2.05, d (4.4); 1.71–1.59, m 28.0, CH2 
12 2.47, m; 2.25–2.31, m 32.1, CH2  2.58, ddd (16.5, 13.0, 6.2); 1.95, dd (16.5, 9.4) 26.8, CH2  1.92, d (1.3); 2.04, m 31.9, CH2 
13  80.8, C   80.3, C   80.8, C 
14  103.4, C   108.5, C   82.3, C 
15  217.0, C   209.7, C   169.5, C 
16 3.23, s 55.6, CH  3.26, s 55.3, CH  2.60, s 51.1, CH 
17  83.6, C   81.9, C   83.9, C 
18  173.5, C   173.7, C   173.3, C 
19 1.65, s 15.3, CH3  1.78, s 19.8, CH3  1.36, s 21.2, CH3 
20  83.9, C   82.6, C   82.5, C 
21 2.02, s 22.3, CH3  2.32, s 22.9, CH3  1.76, s 22.3, CH3 
22 4.73, br. s 77.6, CH  4.75, m 78.0, CH  4.58, dd (4.4, 1.4) 76.1, CH 
23 2.14–2.19, m; 1.92, d (14.9) 27.5, CH2  2.11, m 33.1, CH2  1.97, m 33.0, CH2 
24  36.0, C   32.0, C   29.7, C 
25 3.42, m 42.4, CH  3.05, d (3.8) 51.2, CH  2.57, dd (11.4, 2.3) 41.7, CH 
26  173.0, C   168.1, C   169.4, C 
27 1.29, d (7.5) 17.5, CH3  4.02, dd (13.4, 3.9); 4.83, dd (13.4, 4.5) 62.4, CH2  4.48, dd (12.7, 3.3); 4.32, m 61.7 , CH2 
28 1.47, s 26.4, CH3  1.30, s 26.1, CH3  1.45, s 31.7, CH3 
OMe       3.27, s 55.7, CH3 
ain pyridine-d5, bin CDCl3. 
    
Figure 2.  Key HMBC (H→C) and ROESY(H H) 
correlations of compound 2 
 
Figure 1.  Key HMBC (H→C) and ROESY(H H) 
correlations of compound 1 
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The structures of five known steroidal compounds, physalin 
Z (4)22, physalin C (5)24, physalin I (6)25, physalin P (7)26, 
25,27-dihydro-4,7-dedehydro-7-deoxyneophysalin A (8)27, 
were elucidated in comparison to their spectroscopic data with 
those reported in the literature. 
 
Experimental Section 
General Experimental Procedures. Column chromatog-
raphy (CC): silica gel (100–200 mesh, 200–300 mesh;  
Qingdao Marine Chemical Co., Ltd.), Sephadex LH-20 
(Pharmacia). Thin-layer chromatography (TLC): silica gel 
60F254 (Qingdao Marine Chemical Co., Ltd.). Optical rotations: 
Jasco P-1020 polarimeter. UV Spectra: Shimadzu UV-2401 
PC spectraphotometer. IR Spectra: Bruker Tensor-27 infrared 
spectrophotometer, with KBr pellets in cm–1. NMR Spectra: 
Bruker Bruker Avance III-600MHz spectrometer; chemical 
shifts δ were recorded as ppm relative to TMS, coupling  
constants J in Hz. ESIMS: API QSTAR Pulsar spectrometer; 
HREIMS: Waters Autospec Premier P776. 
 
Plant Material. The calyces of Phsalis alkekengi var. 
franchetii were purchased in Kunming CTM market, Kunming 
city, Yunnan province at December 2011 and were identified 
by Prof. Xi-Wen Li who was botanic taxonomist in Kunming 
Institute of Botany. 
 
Extraction and Isolation. Dried calyces (15 kg) of P. 
alkekengi var. franchetii were extracted with 80% EtOH under 
reflux. The extract was suspended in water (5 L) and then  
partitioned successively with PE (petroleum ether) (8 L  4) 
and EtOAc (8 L  5). The EtOAc-soluble layer (evaporated 
under vacuum to get 250 g) eluted successively with CHCl3, 
CHCl3-MeOH (100:1), CHCl3-MeOH (20:1), and CHCl3-
MeOH (5:1). Then, the CHCl3-MeOH (100:1) portion (80 g) 
was chromatographed on a silica gel column using a gradient 
of CHCl3-CH3OH (100:0 to 0:100), which yielded five  
fractions (1–5). Fraction 2 was successively subjected to  
RP-18, Sephadex LH-20 and silica gel to derive subfractions 
I–IV. Subfraction II was further separated over silica gel with 
CHCl3-CH3OH (120:1) to yield compound 3 (5 mg), 6 (4 mg), 
7 (10 mg) and 8 (3 mg). Subfraction III was subjected to semi-
preparative HPLC (CH3CN-H2O, 50:50) to produce 4 (1 mg) 
and 5 (1 mg). Fraction 3 was successively subjected to RP-18, 
Sephadex LH-20 and separated over silica gel with CHCl3-
CH3OH (80:1) to yield 1 (2 mg) and 2 (6 mg). 
 
Physalin III (1): white powder; [α] 21D   – 29.33 (c 0.2, 
CHCl3); UV (CHCl3): λmax (log ε): 240 (3.36) nm; IR (KBr): 
vmax 3430, 2924, 1787, 1758, 1728, 1462, 1376, 1218, 1073, 
1041 cm–1; 1H and 13C NMR: see Table 1. Negative ESIMS: 
559 ([M – H]–). HREIMS: 560.1885 [M]+ (calcd. for 
C28H32O12, 560.1894). 
 
Physalin IV (2): colorless needle crystal (CHCl3); [α]16D   –
114.40 (c 0.1, MeOH); UV (MeOH): λmax (log ε): 201 (4.23) 
nm; IR (KBr): vmax 3431, 1781, 1729, 1632, 1383, 1374, 1167, 
1134, 1065 cm–1; 1H and 13C NMR: see Table 1. Positive 
ESIMS: 583 ([M  Na]+). HREIMS: 560.1854 [M]+ (calcd. for 
C28H32O12, 560.1894). 
 
3-O-Methylphysalin X (3): yellow powder; [α]18D   – 16.00 
(c 0.1, pyridine); UV (MeOH): λmax (log ε): 225 (3.77), 201 
(3.80) nm; IR (KBr): vmax 3432, 2923, 1786, 1629 cm–1; 1H 
and 13C NMR: see Table 1. Positive ESIMS: 563 ([M  Na]+). 
HREIMS: 540.1933 [M]+ (calcd. for C29H32O10, 540.1995). 
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